Table 4.
Analysis of survival after brain metastasis diagnosis
| Survival (months) | P value | |
| PD-L1 brain-metastasis expression | ||
| Yes | 20 | 0.9 |
| No | 19 | |
| CD8 peritumoral brain metastasis expression | ||
| Low | 21 | 0.3 |
| High | 18 | |
| CD8 intratumoral brain metastasis expression | ||
| Low | 19 | 0.4 |
| High | 18 | |
| CD8 brain metastasis and primary tumor expression association | ||
| Similarly high in the two compartments | 12 | 0.7 |
| Similarly low in the two compartments | 14 | |
| Higher in the brain metastasis than the primary tumor | 21 | |
| Lower in the brain metastasis than the primary tumor | 19 | |
| Primary tumor origin | ||
| Lung | 14 | 0.03 |
| Breast | 29 | |
| Melanoma | 7 | |
| GI | 11 | |
| Renal | 22 | |
| Ovary | 13 | |
| Head neck | 13 | |
| Age at brain metastasis diagnosis (years) | ||
| >60 | 12 | 0.03 |
| ≤60 | 18 | |
| Sex | ||
| Female | 19 | 0.05 |
| Male | 13 | |
| Histological type | ||
| Adenocarcinoma | 19 | 0.05 |
| Squamous cell carcinoma | 13 | |
| Clear cell carcinoma | 22 | |
| Melanoma | 7 | |
| Undifferentiated | 11 | |
| Large-cell neuroendocrine carcinoma | 15 | |
| High-grade serous carcinoma | 10 | |
| Urothelial carcinoma | 23 | |
| Cohort’s molecular characteristics | ||
| Lung tumors | ||
| EGFR mutated | 33 | 0.3 |
| EGFR non mutated | 21 | |
| KRAS mutated | 25 | 0.7 |
| KRAS non mutated | 21 | |
| Breast tumors | ||
| Hormone receptors positive | 26 | 0.4 |
| Hormone receptors negative | 25 | |
| HER2 positive | 34 | 0.03 |
| HER2 negative | 20 | |
| GI tumors | ||
| KRAS mutated | 11 | 0.1 |
| KRAS non mutated | 13 | |
| Melanoma | ||
| BRAF mutated | 22 | 0.08 |
| BRAF non mutated | 6 | |
| Performance status | ||
| 0–1 | 21 | <0.0001 |
| 2–4 | 5 | |
| Symptomatic Bmets requiring corticosteroid treatment | ||
| Yes | 13 | 0.4 |
| No | 16 | |
| Metastases revealing the primary tumor | ||
| Yes | 12 | 0.7 |
| No | 13 | |
| Multiples Bmets | ||
| Yes | 10 | 0.2 |
| No | 14 | |
| Size of brain metastasis (mm) | ||
| ≤30 | 12 | 0.5 |
| >30 | 11 | |
| Bmets location | ||
| Frontal | 13 | 0.3 |
| Cerebellar | 11 | |
| Occipital | 21 | |
| Parietal | 16 | |
| Temporal | 13 | |
| T stage of the primary tumor | ||
| 1–2 | 20 | 0.4 |
| 3–4 | 11 | |
| N stage of the primary tumor | ||
| N− | 13 | 0.6 |
| N+ | 17 | |
| M stage of the primary tumor | ||
| M0 | 17 | 0.2 |
| M1 | 12 | |
| Adjuvant treatment after metastatectomy | ||
| Yes | 17 | 0.002 |
| No | 5 | |
| Resection of the primary tumor | ||
| Yes | 16 | 0.4 |
| No | 9 | |
| Complete resection of brain metastasis | ||
| Yes | 14 | 0.8 |
| No | 13 | |
Bmets, brain metastases; GI, gastrointestinal; HER2, human epidermal growth factor receptor 2; PD-L1, programmed death ligand 1.